Menu

sections

Back to all videosWelcome/IntroductionAreas of InterestEvidence & InsightsImplications for Day-to-Day Care

Language

Contact

esmo2026@lumivara.com+44 1234 5678

All content is educational in intent, non-promotional, and intended for registered healthcare professionals.

Congress Demo: Lumivara - Patient Information Library

Areas of Interest โ€” Congress Demo: Lumivara

Evolving HER2-Low Paradigm: Key Questions at ESMO
0:27

Evolving HER2-Low Paradigm: Key Questions at ESMO

Congress Demo: Lumivara
Approved by Congress Demo: Lumivara

Published: 1 February 2026

Review due: 1 February 2029

LUMINATE-1: Primary Analysis and Efficacy Outcomes
0:29

LUMINATE-1: Primary Analysis and Efficacy Outcomes

Congress Demo: Lumivara
Approved by Congress Demo: Lumivara

Published: 1 February 2026

Review due: 1 February 2029

Biomarker Stratification: Optimising Patient Selection
0:19

Biomarker Stratification: Optimising Patient Selection

Congress Demo: Lumivara
Approved by Congress Demo: Lumivara

Published: 1 February 2026

Review due: 1 February 2029

Return Home

Still have questions?

esmo2026@lumivara.com+44 1234 5678

Important Information

This educational microsite has been developed and supported by Aurexion Therapeutics. Please note: This content is intended for healthcare professionals only. Information presented reflects scientific data and expert interpretation from the ESMO Congress and should be considered alongside primary sources, full congress materials, clinical guidelines, and local prescribing information. Treatment decisions should always be made in accordance with local regulatory requirements and individual patient needs.

Powered by 4Cori

Patient education videos you can trust

ยฉ 2026 Congress Demo: Lumivara. All rights reserved.

Privacy

Hosted by 4Cori Ltd.

We use analytics cookies

With your consent, we use analytics cookies to understand how this library is used and improve it. Theyโ€™re only set if you accept. You can decline and still use the site normally. Cookie policy.